Advertisement
Singapore markets closed
  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     
  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • FTSE 100

    7,879.26
    +2.21 (+0.03%)
     
  • Bitcoin USD

    64,517.83
    +729.02 (+1.14%)
     
  • CMC Crypto 200

    1,364.92
    +52.30 (+4.15%)
     
  • S&P 500

    5,003.28
    -7.84 (-0.16%)
     
  • Dow

    37,974.74
    +199.36 (+0.53%)
     
  • Nasdaq

    15,485.82
    -115.68 (-0.74%)
     
  • Gold

    2,402.90
    +4.90 (+0.20%)
     
  • Crude Oil

    83.20
    +0.47 (+0.57%)
     
  • 10-Yr Bond

    4.6230
    -0.0240 (-0.52%)
     
  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     
  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     
  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

Biogen Unlikely To See Spinraza Rival In 2018 As AveXis Delayed

Biogen Unlikely To See Spinraza Rival In 2018 As AveXis Delayed

Biogen and Ionis are unlikely to see a competitor to Spinraza in 2018, as rival AveXis faces a significant delay for its competing drug.